Table 1.
Baseline Characteristics (SD, IQR, or Percentage) | ||
---|---|---|
Exposed Group | Unexposed Group | |
Number of patients | 80 657 | 161 314 |
Median follow‐up period (person y) | 2.3 (IQR 0.9–5.1) | 2.2 (IQR 0.7–4.9) |
Age at cohort entry (y) | 23.3 (SD 7.3) | 23.4 (SD 7.2) |
Age when maltreatment occurred (y) | 9.6 (SD 5.2) | … |
Sex; Male (%) | 33 614 (41.7%) | 67 228 (41.7%) |
Body mass index | ||
<25 kg/m2 | 24 091 (29.9%) | 56 694 (35.2%) |
25–30 kg/m2 | 7642 (9.5%) | 18 659 (11.6%) |
>30 kg/m2 | 6322 (7.8%) | 11 132 (6.9%) |
Not available | 42 602 (52.9%) | 74 829 (46.4%) |
Smoking status | ||
Current smoker | 30 462 (37.8%) | 31 517 (19.5%) |
Noncurrent/not available | 50 195 (62.2%) | 129 797 (80.5%) |
Townsend index | ||
(Least deprived) 1 | 6296 (7.8%) | 27 027 (16.8%) |
2 | 7295 (9.8%) | 25 086 (15.6%) |
3 | 13 469 (16.7%) | 29 771 (18.5%) |
4 | 19 116 (23.7%) | 29 857 (18.5%) |
5 | 19 860 (24.6%) | 22 849 (14.2%) |
Not available | 13 991 (17.4%) | 26 725 (16.6%) |
Charlson comorbidity index | ||
(Least comorbid) 0 | 59 352 (73.6%) | 130 956 (81.2%) |
1 | 19 975 (24.8%) | 28 735 (17.8%) |
2 | 888 (1.1%) | 1178 (0.7%) |
3 | 276 (0.3%) | 289 (0.2%) |
4 and above | 166 (0.2%) | 156 (0.1%) |
Lipid‐lowering drug use | 309 (0.4%) | 777 (0.5%) |
Pre‐existing cardiometabolic disease | ||
All cardiovascular disease | 395 (0.5%) | 345 (0.2%) |
Ischemic heart disease | 115 (0.1%) | 115 (0.1%) |
Heart failure | 43 (0.1%) | 50 (0.0%) |
Stroke/transient ischemic attack | 214 (0.3%) | 160 (0.1%) |
Peripheral vascular disease | 56 (0.1%) | 51 (0.0%) |
Hypertension | 633 (0.8%) | 1111 (0.7%) |
Diabetes mellitus | 556 (0.7%) | 631 (0.4%) |
IQR indicates interquartile range.